Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody plus GM-CSF as second-line treatment for driver-negative advanced non-small cell lung cancer
ChiCTR2100045480Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-1 Monoclonal Antibody and sargramostim in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Objective response rate. Started May 2021; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibodysargramostim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100045480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045480.